| Ytd | 196.64% | |
| 1y | 347.30% |
| Open | 40.75 | Prev Close | 40.98 | Low | 39.16 | High | 41.34 | Mkt Cap | 5.34B |
| Vol | 2.69M | Avg Vol | 2.97M | EPS | -3.43 | P/E | N/A | Forward P/E | -21.18 |
| Beta | 2.26 | Short Ratio | 4.30 | Inst. Own | 88.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 43.53 | 200-d Avg | 24.26 | 1yr Est | 67.47 |
DFTX News
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"),
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Top analysts changed outlook on top names. See analyst ratings page for all changes.
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX)
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and r
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Bu
RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperfor
Wells Fargo analyst Benjamin Burnett maintains Definium Therapeutics (NASDAQ:DFTX) with a Overwei
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform a
Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Voyage, its Phase III stu
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Gener
Definium Therapeutics remains a 'Strong Buy' following positive phase 3 VOYAGE data for DT120 ODT in
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the
Late-stage clinical biopharmaceutical firm Definium Therapeutics, Inc. (NASDAQ:DFTX) has announced h
Definium Therapeutics says positive Phase 3 trial results for DT120, shows significant and rapid sym
Definium Therapeutics unveiled the second of two positive Phase 3 studies for its LSD-based drug. Th
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p
Topline results from Voyage, its first Phase 3 study of DT120 (lysergide) Orally Disintegrating Tabl
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"),
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overwe
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Definium Therapeutics NASDAQ: DFTX said it expects to report top-line results from its Phase III VOY
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX),
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
The average of price targets set by Wall Street analysts indicates a potential upside of 34.9% in De
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biophar
Wells Fargo analyst Benjamin Burnett initiates coverage on Definium Therapeutics (NASDAQ:DFTX) wi
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overwe
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea
GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervas
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in De
Data highlight the challenges of achieving response and sustained remission in newly diagnosed and e
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”),
Stifel analyst Paul Matteis maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises t
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Bu
Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,
Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial re
Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and r
Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signal
Top Wall Street analysts changed their outlook on top names. Complete view of changes, incl. upgrade
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform a
Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the
Definium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stag
Leerink Partners analyst Marc Goodman maintains Definium Therapeutics (NASDAQ:DFTX) with a Outper
Oppenheimer analyst Jay Olson maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regul